619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II

Type and degree number of immunophenotypic abnormalities refine multiparameter flow cytometry MFC based measurable residual disease MRD testing in adults allografted for Acute Myeloid Leukemia AML in morphologic remission

Monitoring of CNS involvement in AML using ultrahigh sensitivity next generation sequencing of cell free DNA

A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML

A novel multi target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia

Comparable efficacy of CR CRh and CRi in pediatric acute myeloid leukemia A report from the Japan Children s Cancer Group